A chronological archive of the company’s corporate announcements since 2011 — regulatory filings and clearances, patents granted and published, transactions, and intellectual-property enforcement — with links to the original releases. For media inquiries, contact us.
Dr. Kwon, Chief Medical Officer of Aquavit Pharmaceuticals, assumes executive leadership of the Korean manufacturing and research company alongside his clinical role. A neurosurgeon and clinical neuroscientist, he holds a current appointment at Columbia University as Assistant Professor of Neurological Sciences.
Swiss trade coverage of the acquisition, noting Axon’s founding in Geneva in 2022 and its move to Zug.
Aquavit Pharmaceuticals AG, established in the Canton of Zug, acquires Axon Technologies AG — formerly Genève Technologies — bringing predictive modeling, drug-discovery pipelines, AI-powered PITO (Personalized Injection Treatment Optimizer) and clinical-trial data analysis in-house. Certified 23 September 2025 by the notary of the Canton of Zug.
The FDA clears two investigational new drug applications, permitting clinical trials to begin in axillary and palmar hyperhidrosis.
An IND for intradermal aqubotulinumtoxinA delivered through the microchannel platform, for skin quality in the face and neck.
International publication of the microchannel delivery family, subsequently published in Europe as EP 4161627.
The United States District Court for the Southern District of New York awards $10,088,380.72 in damages, together with $7,281,000.00 in sanctions for contemptuous conduct.
An additional investigational new drug application extending the toxin programme to palmar hyperhidrosis.
Two investigational new drug applications filed, covering hyperhidrosis indications and pan-facial microinjection.
A GlobalData thematic assessment ranks Aquavit second among companies surveyed for diversity of application in microneedle-based delivery.
The court imposes a permanent injunction against the manufacture and sale of counterfeit product, following a finding of contempt earlier in the year.
Aquavit joins an American Academy of Dermatology initiative to increase the number of Black, Latino and Indigenous physicians in dermatology.
An investigational new drug application for botulinum toxin type A in moderate to severe glabellar lines.
Continued enforcement in the United States, citing United States Patent No. 10,980,865, after the cancellation of the counterfeiter’s European trademark.
Recognition by Business Connect Magazine.
A notice of allowance issued under the USPTO prioritized-examination pilot programme for the self-administrable vaccine delivery technology.
United States Patent 10,980,865 granted on application 14/909,954, covering repeated-motion microinjection for the delivery of bioactive compositions.
Korean trade coverage of the ten-year exclusive licence and supply arrangement for the United States and Canada, characterized at the time as up to approximately KRW 400 billion in royalties and milestone payments.
The EUIPO invalidates the counterfeiter’s European Union trademark registration on grounds of bad faith.
An exclusive United States and Canada license for a botulinum toxin type A asset already approved in more than eight countries elsewhere, supported by an equivalency study against onabotulinumtoxinA conducted outside the United States.
United States Patent No. 10,894,062, granted 19 January 2021, covering injectable vitamin supplement compositions.
A registered Community design asserted by the counterfeiter is declared invalid, with costs awarded to Aquavit.
A United States application extending the delivery platform to exosome payloads.
Default judgment entered in the Southern District of New York against one of the defendants in the counterfeiting proceedings.
An application filed under the USPTO prioritized-examination pilot programme for a self-administrable epidermal vaccine delivery technology.
The court orders forfeiture of infringing profits together with a substantial share of Aquavit’s legal fees, and orders the removal of infringing promotional material.
An application extending the delivery platform to ophthalmic routes of administration in age-related macular degeneration and juvenile macular dystrophy.
The delivery and vaccine platform presented to the international biotechnology industry.
A United States application applying the delivery platform to oncology immunotherapy.
Independent coverage of the platform in the drug-delivery trade press.
Two applications filed, covering the delivery platform and vaccine compositions for immunization.
A United States application covering intradermal allergen delivery for allergy assessment.
Criminal referral in South Korea following the seizure of counterfeit product.
The Southern District of New York grants preliminary injunctive relief in the patent and trademark infringement proceedings.
Counterfeit devices seized at a major Korean medical device exhibition.
Acquisition of an ISO 13485 certified GMP manufacturing facility near Seoul, subsequently operated under the Aquavit name.
Institutional review board approval for a randomized split-periorbital study across six investigators.
United States Patent 9,675,519 granted for the APOLLO™ platform (program PITO-001), following European Patent EP 2667965 issued in July 2016.
Korean registration of the microchannel delivery device.
An FDA-compliant research and manufacturing facility established in South Korea under a five-year agreement with a national university technopark.
The first configuration of the microchannel delivery series reaches the professional market.
A worldwide, perpetual licence agreement with Huons Co., Ltd., with both companies committing development investment to the AQT-001 delivery system.
The original licence for the microneedle delivery technology. The counterparty to this agreement later became the defendant in the company’s United States and European enforcement proceedings.
A term sheet covering PITO-001 and a companion programme, with the partner committing capital toward international regulatory registration.
An alliance covering the PITO-001 personalized treatment platform.
A big-data and scientific-informatics alliance with Accelrys Software Inc. (NASDAQ: ACCL), covering the PITO-001 and MAV-403 programmes.
A collaboration covering the IBX-001 formulation programme in Asian markets.
The company’s development strategy presented at the University of California, Berkeley, Haas School of Business.
This archive lists corporate announcements — regulatory filings and clearances, patent grants and publications, transactions, corporate structure and intellectual-property enforcement. Personnel announcements, conference appearances and consumer product news are not included. Links are to the original wire release or to independent coverage; statements in those releases speak as of their date and have not been updated.